Shandong Xinhua Pharmaceutical Co., Ltd. (00719) announced its 2023 results, with operating revenue of about 8.1 billion yuan, an increase of 7...
According to the Zhitong Finance App, Shandong Xinhua Pharmaceutical Co., Ltd. (00719) announced its 2023 results, with operating income of about 8.1 billion yuan, up 7.97% year on year; net profit attributable to shareholders of listed companies was about 496.5 million yuan, up 20.79% year on year; basic earnings per share were 0.74 yuan, with a final dividend of 0.25 yuan per share (tax included).
The international API market dominated the product market and prices remained basically stable; the domestic market gave full play to its comprehensive advantages, and revenue and profits achieved significant year-on-year growth. Four formulation products won the bid, and 18 product alliances won the bid. The annual sales revenue of the pharmaceutical processing and export business increased 48.73% year-on-year. The medical trade business successfully passed the modern pharmaceutical logistics qualification certification. Xinhua Health accelerated the development of two-way cross-border business and private brand building, and revenue increased 21.16% year over year. A total of 18 new products were launched on the market throughout the year. Product technology transformation projects and strong chain fixed chain projects are advancing at an accelerated pace.